Literature DB >> 11310478

The tramadol option.

J A Desmeules1.   

Abstract

Tramadol is an option for the treatment of rheumatological pain. Its mode of action and safety profile distinguishes it from other opioids. Tramadol differs from other opioids by combining a weak opioid and a monoaminergic mode of action. It is effective in different types of moderate-to-severe pain, including neuropathic pain. Moreover, as the mode of action of tramadol does not overlap with that of NSAIDs, it is a useful agent to be combined with these drugs. Tramadol induces fewer opioid adverse reactions for a given level of analgesia compared with traditional opioids. Common adverse reactions of tramadol such as nausea and dizziness, which usually occur only at the beginning of therapy and attenuate over time, can be further minimized by up-titrating the drug over several days. Dose adjustment is only necessary in patients over 75 years of age, or in those with either hepatic or renal insufficiency. Tramadol should be avoided or used with caution in epileptics, or in individuals who are receiving seizure-threshold lowering drugs. Finally, tramadol has a low risk of abuse because it has only a weak opioid effect and its monoaminergic action could inhibit the development of dependence. The low abuse potential of tramadol has been demonstrated by postmarketing surveillance data.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11310478

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  9 in total

Review 1.  [Polypharmacy and pain treatment].

Authors:  Markus Gosch; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Bernhard Iglseder; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger
Journal:  Wien Med Wochenschr       Date:  2010-06

2.  Angioedema induced by tramadol--a potentially life-threatening condition.

Authors:  Pär Hallberg; Gunilla Brenning
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain.

Authors:  Sebastiano Mercadante; Edoardo Arcuri; Flavio Fusco; Walter Tirelli; Patrizia Villari; Carlo Bussolino; Tiziana Campa; Franco De Conno; Carla Ripamonti
Journal:  Support Care Cancer       Date:  2005-01-12       Impact factor: 3.603

Review 4.  Translational pain research: achievements and challenges.

Authors:  Jianren Mao
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

5.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

Review 6.  What is new in neuropathic pain?

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2006-11-28       Impact factor: 3.359

7.  Seizures after intravenous tramadol given as premedication.

Authors:  Lalit Kumar Raiger; Udita Naithani; Sonali Bhatia; Sandeep Singh Chauhan
Journal:  Indian J Anaesth       Date:  2012-01

8.  Analysis of medical service use of knee osteoarthritis and knee meniscal and ligament injuries in Korea: a cross-sectional study of national patient sample data.

Authors:  Chang Yong Suh; Yoon Jae Lee; Joon-Shik Shin; Jinho Lee; Me-Riong Kim; Wonil Koh; Yun-Yeop Cha; Byung-Cheul Shin; Eui-Hyoung Hwang; Kristin Suhr; Mia Kim; In-Hyuk Ha
Journal:  BMC Musculoskelet Disord       Date:  2017-11-10       Impact factor: 2.362

Review 9.  Strategies of pain reduction during the bone marrow biopsy.

Authors:  Nikolaj Hjortholm; Emil Jaddini; Kazimierz Hałaburda; Emilian Snarski
Journal:  Ann Hematol       Date:  2012-12-06       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.